Elazar S Rabbani

This inventor holds 122 USPTO granted patents and 33 published patent applications, plus 1 CIPO patent and 20 EPO patents, primarily in Nucleic Acid Detection (CPC class C07H21-00). Top assignees: Enzo Life Sciences, Inc., Enzo Biochem, Inc., Enzo Diagnostics, Inc.. Active years: 1979-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elazar S Rabbani. Retrieved from https://idiyas.com/inventor/elazar-s-rabbani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 122 (Patent Applications = 33)

% Patents Active = 77.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 20 (Patent Applications = 24)

Average Co-Inventor Count = 3.0

ph-index = 18

Forward Citations = 1,983(Granted Patents)

Forward Citations (Not Self Cited) = 1,680(Dec 10, 2025)

Inventors with similar research interests:

Location History:

NY, NY (US) (2015)
New York, NY (US) (1979 - 2024)

Company Filing History:

60 out of 99

Enzo Life Sciences, Inc.

Enzo Diagnostics, Inc.

patents

4. 6 out of 31

Enzo Therapeutics, Inc.

patents

5. 5 out of 7

Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.

patents

6. 1 out of 1

C/o Enzo Biochem, Inc.

Enzo Life Science, Inc. C/o Enzo Biochem Inc.

patent

9. 1 out of 1

Enzo Therapeutics, Inc. C/o Enzo Biochem, Inc.

patent

10. 1 out of 834,570

Other

patents

Years Active: 1979-2024

Loading Chart...

Areas of Expertise:

Fluorescence Quencher

Sphingosine Compounds

Immunomodulatory Compositions

Nucleic Acid Probes

Multisignal Labeling

Cancer Treatment

Assays

Analyte Detection

Quantitative Detection

Synthetic Peptide

Chimeric Compositions

Dual Polarity Analysis

122 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12122921 - Fluorescence quencher polymer conjugates and uses thereof (2024-10-22),

2. 11931344 - Sphingosine pathway modulating compounds for the treatment of coronavirus infection (2024-03-19),

3. 11874281 - Assays for detecting modified compounds (2024-01-16),

4. 11865105 - Sphingosine pathway modulating compounds for the treatment of cancers (2024-01-09),

5. 11745184 - Reduced background immunoassay plates (2023-09-05),

6. 11723895 - Sphingosine pathway modulating compounds for the treatment of coronavirus infection (2023-08-15),

7. 11554111 - Sphingosine pathway modulating compounds for the treatment of coronavirus infection (2023-01-17),

8. 11181528 - Assays for detecting modified compounds (2021-11-23),

9. 11173195 - Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta (2021-11-16),

10. 11066694 - Affinity tag nucleic acid and protein compositions, and processes for using same (2021-07-20),

11. 11028121 - Multisignal labeling reagents and processes and uses therefor (2021-06-08),

12. 10881643 - Sphingosine pathway modulating compounds for the treatment of cancers (2021-01-05),

13. 10709774 - Immunomodulatory pharmaceutical compositions (2020-07-14),

14. 10675255 - Sphingosine pathway modulating compounds for the treatment of cancers (2020-06-09),

15. 10660879 - Sphingosine pathway modulating compounds for the treatment of cancers (2020-05-26),

Title: Innovator Spotlight: Elazar S Rabbani - Pioneering Cancer Treatment Solutions

Introduction:

Elazar S Rabbani, a prolific inventor based in New York, NY, is renowned for his groundbreaking work in the field of oncology. With an impressive portfolio comprising 120 patents, Rabbani has significantly contributed to the advancement of cancer research and treatment methodologies.

Latest Patents:

Among his latest patents is the development of assays for detecting modified compounds. These methods and compositions allow for the precise separation, isolation, and quantification of chemically, enzymatically, or catalytically modified compounds, offering invaluable insights for researchers and healthcare practitioners. Additionally, Rabbani has innovated sphingosine pathway modulating compounds for the treatment of cancers, presenting novel therapeutic approaches for combating various forms of cancer and myeloproliferative disorders.

Career Highlights:

Rabbani's innovative spirit has led him to collaborate with prominent companies such as Enzo Life Sciences, Inc. and Enzo Biochem, Inc., where his expertise has been instrumental in driving forward cutting-edge research and product development initiatives. His dedication to revolutionizing cancer treatment has earned him a reputation as a leader in the biopharmaceutical industry.

Collaborations:

Throughout his career, Rabbani has had the privilege of working alongside accomplished professionals such as Jannis G Stavrianopoulos and James J Donegan. These collaborations have not only enriched his own research endeavors but have also fostered a culture of innovation and knowledge-sharing within the scientific community.

Conclusion:

Elazar S Rabbani's remarkable contributions to cancer research and treatment underscore his unwavering commitment to pushing the boundaries of scientific exploration. With a diverse portfolio of patents and a history of successful collaborations, Rabbani continues to inspire future generations of inventors and researchers in the pursuit of transformative healthcare solutions.

Profile summary based on public USPTO records.